IQVIA Holdings Inc. $IQV Holdings Lifted by Coronation Fund Managers Ltd.

Coronation Fund Managers Ltd. raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 382.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 69,434 shares of the medical research company’s stock after purchasing an additional 55,043 shares during the quarter. Coronation Fund Managers Ltd.’s holdings in IQVIA were worth $13,188,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in IQV. Florida Financial Advisors LLC increased its position in IQVIA by 14.2% in the 3rd quarter. Florida Financial Advisors LLC now owns 1,485 shares of the medical research company’s stock valued at $282,000 after acquiring an additional 185 shares during the period. CENTRAL TRUST Co grew its stake in shares of IQVIA by 15.9% in the third quarter. CENTRAL TRUST Co now owns 1,396 shares of the medical research company’s stock worth $265,000 after purchasing an additional 191 shares in the last quarter. Metis Global Partners LLC increased its holdings in shares of IQVIA by 6.0% during the third quarter. Metis Global Partners LLC now owns 11,136 shares of the medical research company’s stock valued at $2,115,000 after purchasing an additional 632 shares during the period. Abich Financial Wealth Management LLC bought a new stake in shares of IQVIA during the third quarter valued at about $163,000. Finally, Assetmark Inc. lifted its holdings in IQVIA by 10.2% in the third quarter. Assetmark Inc. now owns 129,189 shares of the medical research company’s stock worth $24,538,000 after purchasing an additional 11,928 shares during the period. 89.62% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on IQV shares. JPMorgan Chase & Co. dropped their price target on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. Stifel Nicolaus lowered their price objective on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. UBS Group lowered their price target on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Finally, Citigroup cut their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $238.20.

IQVIA Price Performance

Shares of NYSE:IQV opened at $166.70 on Friday. The company’s fifty day moving average is $223.12 and its two-hundred day moving average is $209.07. The company has a market cap of $28.39 billion, a P/E ratio of 21.21, a price-to-earnings-growth ratio of 1.61 and a beta of 1.37. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a quick ratio of 0.70, a current ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.IQVIA’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.